Relapse during treatment (4 to 12 months) · SSNS in children
Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Adverse effects: ANCA positive/arthritis · SSNS in children
Levamisole showed no clear difference in adverse effects: ANCA positive/arthritis compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Relapse · SSNS in children
It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).
4 findings from 1 review
RR 2.14 [0.22, 20.95]
2 studies · 97 participants
Very low
RR 1.17 [0.76, 1.81]
2 studies · 97 participants
Low
RR 0.89 [0.68, 1.16]
1 study · 40 participants
Low
Show 1 more finding
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: infection · SSNS in children
Levamisole showed no clear difference in adverse effects: infection compared with cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects: abnormal liver function tests · SSNS in children
It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention (leading to discontinuation) · participants with recurrent herpes labialis
1 finding from 1 review
Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Frequent relapses · SSNS in children
Mycophenolate mofetil showed no clear difference in frequent relapses at 12 months compared with levamisole (low certainty).
1 finding from 1 review
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Peritonitis · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: peritonitis compared with levamisole (very low certainty).
1 finding from 1 review
Abdominal pain · SSNS in children
Mycophenolate mofetil showed no clear difference in adverse effects: abdominal pain compared with levamisole (low certainty).
1 finding from 1 review
Adverse effects: anaemia · SSNS in children
It is very uncertain whether mycophenolate mofetil changes adverse effects: anaemia compared with levamisole (very low certainty).
1 finding from 1 review